226 related articles for article (PubMed ID: 25638467)
1. The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia.
Bilir C; Engin H; Can M; Temi YB; Demirtas D
Med Oncol; 2015 Mar; 32(3):56. PubMed ID: 25638467
[TBL] [Abstract][Full Text] [Related]
2. The correlation between a chronic inflammatory marker Tartrate-resistant acid phosphatase 5a with cancer cachexia.
Wu YY; Chao TY; Liu HY; Huang TC; Chen JH; Dai MS; Janckila A; Lai SW; Chang PY
J BUON; 2015; 20(1):325-31. PubMed ID: 25778334
[TBL] [Abstract][Full Text] [Related]
3. Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia.
Burney BO; Hayes TG; Smiechowska J; Cardwell G; Papusha V; Bhargava P; Konda B; Auchus RJ; Garcia JM
J Clin Endocrinol Metab; 2012 May; 97(5):E700-9. PubMed ID: 22419719
[TBL] [Abstract][Full Text] [Related]
4. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients.
Kayacan O; Karnak D; Beder S; Güllü E; Tutkak H; Senler FC; Köksal D
Am J Clin Oncol; 2006 Aug; 29(4):328-35. PubMed ID: 16891858
[TBL] [Abstract][Full Text] [Related]
5. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report.
Del Fabbro E; Hui D; Nooruddin ZI; Dalal S; Dev R; Freer G; Roberts L; Palmer JL; Bruera E
J Pain Symptom Manage; 2010 Jun; 39(6):1016-24. PubMed ID: 20457506
[TBL] [Abstract][Full Text] [Related]
6. Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer.
Dev R; Hui D; Del Fabbro E; Delgado-Guay MO; Sobti N; Dalal S; Bruera E
Cancer; 2014 May; 120(10):1586-93. PubMed ID: 24577665
[TBL] [Abstract][Full Text] [Related]
7. [Plasma concentration of leptin, neuropeptide Y and tumor necrosis factor alpha in patients with cancers, before and after radio- and chemotherapy].
Kowalczuk A; Wiecek A; Franek E; Kokot F
Pol Arch Med Wewn; 2001 Aug; 106(2):657-68. PubMed ID: 11926139
[TBL] [Abstract][Full Text] [Related]
8. Systemic inflammation in patients with COPD and pulmonary hypertension.
Joppa P; Petrasova D; Stancak B; Tkacova R
Chest; 2006 Aug; 130(2):326-33. PubMed ID: 16899829
[TBL] [Abstract][Full Text] [Related]
9. Weight loss and resting energy expenditure in male patients with newly diagnosed esophageal cancer.
Wu J; Huang C; Xiao H; Tang Q; Cai W
Nutrition; 2013; 29(11-12):1310-4. PubMed ID: 24012284
[TBL] [Abstract][Full Text] [Related]
10. Relationships of emerging biomarkers of cancer cachexia with quality of life, appetite, and cachexia.
Lipshitz M; Visser J; Anderson R; Nel DG; Smit T; Steel HC; Rapoport BL
Support Care Cancer; 2024 May; 32(6):349. PubMed ID: 38744744
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity.
Khaodhiar L; Ling PR; Blackburn GL; Bistrian BR
JPEN J Parenter Enteral Nutr; 2004; 28(6):410-5. PubMed ID: 15568287
[TBL] [Abstract][Full Text] [Related]
12. L-carnitine ameliorates cancer cachexia in mice by regulating the expression and activity of carnitine palmityl transferase.
Liu S; Wu HJ; Zhang ZQ; Chen Q; Liu B; Wu JP; Zhu L
Cancer Biol Ther; 2011 Jul; 12(2):125-30. PubMed ID: 21532335
[TBL] [Abstract][Full Text] [Related]
13. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels.
Borazan A; Ustün H; Ustundag Y; Aydemir S; Bayraktaroglu T; Sert M; Yilmaz A
Mediators Inflamm; 2004 Jun; 13(3):201-4. PubMed ID: 15223612
[TBL] [Abstract][Full Text] [Related]
14. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children.
Erbağci AB; Tarakçioğlu M; Coşkun Y; Sivasli E; Sibel Namiduru E
Clin Biochem; 2001 Nov; 34(8):645-50. PubMed ID: 11849625
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.
Tas F; Duranyildiz D; Argon A; Oğuz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2005; 22(4):353-8. PubMed ID: 16260852
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein, interleukin-6, and tumor necrosis factor-alpha levels in overweight and healthy adults.
Chaikate S; Harnroongroj T; Chantaranipapong Y; Puduang S; Mahaisiriyodom A; Viroonudomphol D; Singhasivanon P; Schelp FP; Tornee S; Tribunyatkul S; Changbumrung S
Southeast Asian J Trop Med Public Health; 2006 Mar; 37(2):374-81. PubMed ID: 17125002
[TBL] [Abstract][Full Text] [Related]
17. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia?
Scheede-Bergdahl C; Watt HL; Trutschnigg B; Kilgour RD; Haggarty A; Lucar E; Vigano A
Clin Nutr; 2012 Feb; 31(1):85-8. PubMed ID: 21855185
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of cachexia in newly diagnosed head and neck cancer patients: An exploratory study.
Jager-Wittenaar H; Dijkstra PU; Dijkstra G; Bijzet J; Langendijk JA; van der Laan BFAM; Roodenburg JLN
Nutrition; 2017 Mar; 35():114-118. PubMed ID: 28241978
[TBL] [Abstract][Full Text] [Related]
19. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
[TBL] [Abstract][Full Text] [Related]
20. Association of C-reactive protein, tumor necrosis factor-alpha, and interleukin-6 with chronic kidney disease.
Lee BT; Ahmed FA; Hamm LL; Teran FJ; Chen CS; Liu Y; Shah K; Rifai N; Batuman V; Simon EE; He J; Chen J
BMC Nephrol; 2015 May; 16():77. PubMed ID: 26025192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
